KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $791.3 million.

  • West Pharmaceutical Services' Cash & Equivalents rose 6328.93% to $791.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $791.3 million, marking a year-over-year increase of 6328.93%. This contributed to the annual value of $791.3 million for FY2025, which is 6328.93% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Cash & Equivalents stood at $791.3 million, which was up 6328.93% from $628.5 million recorded in Q3 2025.
  • West Pharmaceutical Services' Cash & Equivalents' 5-year high stood at $898.6 million during Q3 2023, with a 5-year trough of $404.2 million in Q1 2025.
  • In the last 5 years, West Pharmaceutical Services' Cash & Equivalents had a median value of $677.8 million in 2021 and averaged $665.6 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Cash & Equivalents crashed by 4537.06% in 2024, and later surged by 6328.93% in 2025.
  • West Pharmaceutical Services' Cash & Equivalents (Quarter) stood at $762.6 million in 2021, then grew by 17.27% to $894.3 million in 2022, then decreased by 4.52% to $853.9 million in 2023, then crashed by 43.25% to $484.6 million in 2024, then soared by 63.29% to $791.3 million in 2025.
  • Its last three reported values are $791.3 million in Q4 2025, $628.5 million for Q3 2025, and $509.7 million during Q2 2025.